Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0...
Aadi Bioscience, Inc. (NASDAQ:AADI), an oncology therapeutics company applying advanced technologies to established tumor biolo...
Aadi Bioscience secures ADC portfolio license, involving $44 million upfront and $805 million in milestones plus royalties.
Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and H...
Aadi has not provided a specific timeline to complete this process and will provide further updates when appropriate.
All patients who were still receiving benefit at the time the study was halted were transitioned to an expanded access protocol...
Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. The com...
